摘要
目的:调研2019冠状病毒病(coronavirus disease 2019,COVID-19)诊治中抗菌药物的使用情况,了解临床用药习惯,为COVID-19的合理用药提供依据。方法:统计分析某医院2020年2―3月所用抗菌药物的品名、规格、数量、金额、用药频度(defined daily dose system,DDDs),限定日费用(defined daily dose consumption,DDDc),抗菌药物使用强度(antibiotics use density,AUD),构成、使用频率、合并用药等情况。结果:2个月全院共使用抗菌药物12类25种,总金额123.80万元,用量排名前5位的为喹诺酮类药物、三代头孢/β-内酰胺酶抑制剂类药物、抗真菌类、其他类(噁唑烷酮)及碳青酶烯类药物,占比分别为36.10%,15.86%,14.17%,13.46%及12.73%;DDDs,AUD排名前3位的药品为盐酸莫西沙星片、盐酸莫西沙星氯化钠注射液和注射用头孢哌酮钠舒巴坦钠;合并使用两种及以上抗菌药物的比例为22.36%。结论:COVID-19的用药起点较高,多为广谱、高效抗菌药物,品种、品规数符合抗菌药物管理要求,患者抗菌药物使用率及金额占比均在较为合理的范围内,今后,对于COVID-19的治疗,应在遵循指南的基础上,不断总结临床治疗经验,完善治疗方案,合理应用抗菌药物。
Objective:To explore the prescribing habits of doctors,and to provide basis for rational use of antibiotics in clinical practice via investigating and analyzing the applications of antibiotics in treatment of coronavirus disease 2019(COVID-19)in the designated hospital.Methods:Specification,quantity,amount,defined daily dose system(DDDs),defineddaily dose consumption(DDDc),antibiotics use density(AUD),composition,frequency of use,combined use of antibacterial drugs used in the hospital were analyzed between Feb.2020 and Mar.2020.Results:A total of 25 antibiotic drugs in 12 categories were used.The total cost for antibiotic drugs was 1 million 238 thousand yuan,in which quinolone accounts for 48%,the third generation cephalosporin/lactamase inhibitors accounts for 15.86%,antifungals accounts for 14.17%,oxazolidone accounts for 13.46%,and carbapenms account for 12.73%.The top three drugs of DDDs and AUD were moxifloxacin hydrochloride tablets,moxifloxacin hydrochloride and sodium chloride injection,cefoperazone sodium and sulbactam sodium for injection.The proportion of patients who had been used more than two kinds of antibiotics was 22.36%.Conclusion:Broad-spectrum,high-potency antibiotics are used at the beginning of COVID-19 treatment.The varieties of antibiotics meet the requirements of the management of antibiotics,and the utilization rate of antibiotics and the cost proportion of antibiotics in COVID-19 patients are within a reasonable range.In the future,for the treatment of COVID-19,we should continue to summarize the experience,improve the strategies,and rationally apply antibiotics on the basis of guidelines.
作者
李文斌
张强
王瞳辉
LIWenbin;ZHANG Qiang;WANG Tonghui(Department of Pharmacy,940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army,Lanzhou 730050;Huoshengshan Hospital,Wuhan 430000;Medical Department,940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army,Lanzhou 730050,China)
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2020年第5期571-575,共5页
Journal of Central South University ：Medical Science
